Profile: Esperion Therapeutics Inc (ESPR.OQ)
24 Oct 2014
Esperion Therapeutics, Inc., incorporated in 1998, is a biopharmaceutical company dedicated to the discovery and development of high-density lipoprotein (HDL)-targeted therapies for the treatment of cardiovascular disease. The Company has focused its initial drug discovery and development activities on a novel class of drugs to treat acute and chronic cardiovascular disease. It intends to commercialize a novel class of drugs that focus on a new treatment approach that it calls HDL Therapy, which is based upon Esperion's understanding of HDL function. Through HDL Therapy, the Company intends to exploit, with a portfolio of product candidates, the beneficial properties of HDL in cardiovascular disease.
The Company is developing four product candidates, including three biopharmaceuticals: ETC-588 (LUV); ETC-216 (AIM) and ETC-642 (RLT Peptide), as well as one oral small molecule, now designated ETC-1001 (previously designated ESP 31015). The biopharmaceuticals are being developed for the acute treatment of high-risk atherosclerosis, such as acute coronary syndromes, while the small molecule will target chronic treatment of risk factors associated with cardiovascular disease. Each of these product candidates are designed to enhance the naturally occurring processes in the body that remove excess cholesterol from artery walls and other tissues.
Esperion's product development to date has used in-vitro assays, testing procedures performed outside the body, animal models and human clinical testing. Clinical and pre-clinical studies suggest that its product candidates increase HDL-cholesterol (HDL-C) or its function and enhance the removal of excess cholesterol and other lipids from artery walls and other tissues. Preliminary results in early clinical trials indicate that ETC-588, ETC-642 and ETC-216 increase the mobilization of cholesterol or the removal of cholesterol from arteries and other tissues and delivery of cholesterol to the liver, as evidenced by measurements of the amount of cholesterol in the blood both before and after administration. Third-party published reports of preliminary human clinical studies of compounds that are similar in function and composition to some of its product candidates suggest that these compounds may increase elimination of cholesterol from the body by enhancing the efficiency of the reverse lipid transport (RLT) pathway.
The Company is also pursuing the discovery and development of orally active organic small molecules designed to increase HDL-C levels and/or enhance the function of HDL to stimulate the RLT pathway, as well as decrease low-density lipoportein (LDL) or LDL cholesterol (LDL-C) and triglycerides, another type of lipid or fat. Some of these small molecules may also possess anti-diabetic and anti-obesity properties. It has implemented several strategies to develop potential small-molecule product candidates based on well-known mechanisms by which HDL is produced in the body. One strategy has yielded several classes of active molecules. The Company's drug discovery technologies and scientific and drug development expertise may have potential applicability to the discovery and development of therapies for a broad range of cardiovascular diseases, including treatments for coronary heart disease, peripheral arterial disease (atherosclerosis occurring in arteries near the body's extremities) and stroke.
Esperion Therapeutics Inc
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR MI 48108